123 related articles for article (PubMed ID: 30054907)
1. In regard to "A tale of two clones: Caldesmon staining in the differentiation of cutaneous spindle-cell neoplasms".
Martinez-Ciarpaglini C; Monteagudo C
J Cutan Pathol; 2018 Nov; 45(11):869-870. PubMed ID: 30054907
[No Abstract] [Full Text] [Related]
2. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
[TBL] [Abstract][Full Text] [Related]
3. A tale of two clones: Caldesmon staining in the differentiation of cutaneous spindle cell neoplasms.
Beck EM; Bauman TM; Rosman IS
J Cutan Pathol; 2018 Aug; 45(8):581-587. PubMed ID: 29687929
[TBL] [Abstract][Full Text] [Related]
4. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study.
Ceballos KM; Nielsen GP; Selig MK; O'Connell JX
Am J Clin Pathol; 2000 Nov; 114(5):746-53. PubMed ID: 11068549
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
[TBL] [Abstract][Full Text] [Related]
6. h-Caldesmon as a specific marker of smooth muscle cell differentiation in some soft tissue tumors of the skin.
D'Addario SF; Morgan M; Talley L; Smoller BR
J Cutan Pathol; 2002 Aug; 29(7):426-9. PubMed ID: 12139638
[TBL] [Abstract][Full Text] [Related]
7. Spindle Cell Atypical Fibroxanthoma: Myofibroblastic Differentiation Represents a Diagnostic Pitfall in This Variant of AFX.
Harding-Jackson N; Sangueza M; Mackinnon A; Suster S; Plaza JA
Am J Dermatopathol; 2015 Jul; 37(7):509-14; quiz 515-6. PubMed ID: 26098709
[TBL] [Abstract][Full Text] [Related]
8. h-caldesmon immunoreactivity in atypical fibroxanthoma: implications for the differential diagnosis.
Martinez-Ciarpaglini C; Agustí J; Alvarez E; Hueso L; Terrádez L; Monteagudo C
Pathology; 2018 Apr; 50(3):358-361. PubMed ID: 29490873
[No Abstract] [Full Text] [Related]
9. h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors.
Watanabe K; Tajino T; Sekiguchi M; Suzuki T
Am J Clin Pathol; 2000 May; 113(5):663-8. PubMed ID: 10800398
[TBL] [Abstract][Full Text] [Related]
10. [Pleomorphic and dedifferentiated leiomyosarcoma: a clinicopathologic analysis].
Sun M; Liu JG; Weng QY; Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2018 Feb; 47(2):87-93. PubMed ID: 29429158
[No Abstract] [Full Text] [Related]
11. Immunohistochemical distinction of cutaneous spindle cell carcinoma.
Morgan MB; Purohit C; Anglin TR
Am J Dermatopathol; 2008 Jun; 30(3):228-32. PubMed ID: 18496422
[TBL] [Abstract][Full Text] [Related]
12. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation.
Miettinen MM; Sarlomo-Rikala M; Kovatich AJ; Lasota J
Mod Pathol; 1999 Aug; 12(8):756-62. PubMed ID: 10463476
[TBL] [Abstract][Full Text] [Related]
13. The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. part 2 - tumours and tumour-like lesions.
Eyden B
J Submicrosc Cytol Pathol; 2005 Nov; 37(3-4):231-96. PubMed ID: 16612972
[TBL] [Abstract][Full Text] [Related]
14. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor.
Watanabe K; Kusakabe T; Hoshi N; Saito A; Suzuki T
Hum Pathol; 1999 Apr; 30(4):392-6. PubMed ID: 10208459
[TBL] [Abstract][Full Text] [Related]
15. H-caldesmon expression in myofibroblastoma of the breast: evidence supporting the distinction from leiomyoma.
Magro G; Gurrera A; Bisceglia M
Histopathology; 2003 Mar; 42(3):233-8. PubMed ID: 12605642
[TBL] [Abstract][Full Text] [Related]
16. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.
Hisaoka M; Wei-Qi S; Jian W; Morio T; Hashimoto H
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):302-8. PubMed ID: 11759055
[TBL] [Abstract][Full Text] [Related]
17. Granular cell variant of atypical fibroxanthoma. A case report.
Němejcová K; Dundr P
Cesk Patol; 2014 Jan; 50(1):34-7. PubMed ID: 24624985
[TBL] [Abstract][Full Text] [Related]
18. Malignant fibrous histiocytoma of the esophagus.
Naganuma H; Ohtani H; Sayama J; Sakai N; Taira Y; Shibuya D; Miyazaki A; Sakurada H
Pathol Int; 1996 Jun; 46(6):462-6. PubMed ID: 8869999
[TBL] [Abstract][Full Text] [Related]
19. Localized cutaneous metastases from an atypical fibroxanthoma.
Giuffrida TJ; Kligora CJ; Goldstein GD
Dermatol Surg; 2004 Dec; 30(12 Pt 2):1561-4. PubMed ID: 15606841
[TBL] [Abstract][Full Text] [Related]
20. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
